RPRobert B. Penfold

Robert B. Penfold

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert B. Penfold has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessing and Minimizing Re-identification Risk in Research Data Derived from Health Care Records

    by Gregory E. Simon, Susan M. Shortreed, R. Yates Coley, Robert B. Penfold, Rebecca C. Rossom, Beth E. Waitzfelder, Katherine Sanchez, Frances L. Lynch

    Background: Sharing of research data derived from health system records supports the rigor and reproducibility of primary research and can accelerate research progress through secondary use. But public sharing of such data can create risk of re-identifying individuals, exposing sensitive health information.Method: We describe a framework for assessing re-identification risk that includes: identifying data elements in a research dataset that overlap with external data sources, identifying small classes of records defined by unique combinations of those data elements, and considering the pattern of population overlap between the research dataset and an external source. We also describe alternative strategies for mitigating risk when the external data source can or cannot be directly examined.Results: We illustrate this framework using the example of a large database used to develop and validate models predicting suicidal behavior after an outpatient visit. We identify elements in the research dataset that might create risk and propose a specific risk mitigation strategy: deleting indicators for health system (a proxy for state of residence) and visit year.Discussion: Researchers holding health system data must balance the public health value of data sharing against the duty to protect the privacy of health system members. Specific steps can provide a useful estimate of re-identification risk and point to effective risk mitigation strategies.


  • Open Access

    Antidepressant Use by Youth with Minimal or Mild Depression: Evidence from 3 Health Systems

    by Robert B. Penfold, Christine Stewart, Gregory E. Simon, Susan M. Shortreed, Eric Johnson, Rebecca C. Rossom, Belinda Operskalski, Arne Beck

    There is concern about the prevalence of prescribing antidepressant medications to youth without appropriate diagnoses or who have subthreshold (mild) depression. Electronic records data from 3 large healthcare systems identified youth aged ≤21 years starting a new episode of antidepressant treatment between January 1, 2009, and December 31, 2013. For those with a diagnosis of depression, Patient Health Questionnaire (PHQ9) scores at the time of treatment initiation were used to examine the distribution of symptom severity and patients' demographic and clinical characteristics. Of the 15,460 episodes of treatment, a depression diagnosis was recorded in 95% of the cases. PHQ9 scores were available for 4,329 youth with a diagnosis of depression. Younger age, sex, previous treatment, co-occurring anxiety, treatment setting, concurrent psychotherapy, and site were significant predictors of completing a PHQ9. Among youth with a baseline score, 87% reported moderate or severe symptoms (PHQ9 score ≥ 10) and 13% reported mild or minimal symptoms (PHQ9 < 10). The proportion reporting PHQ9 < 10 when starting treatment decreased with age, ranging from 19% in those aged 13–14 years and 12% in those aged 18–21 years. Patients treated by psychiatrists were 1.54 times (95% Confidence Interval [CI], 1.21–1.97) more likely to have PHQ9 scores < 10 compared with primary care physicians. Patients with prior treatment history (odds ratio = 1.76; 95% CI, 1.45–2.13) and concurrent psychotherapy (odds ratio = 1.24; 95% CI, 1.02–1.52) were more likely to have PHQ9 < 10. In these health systems, prescribing of antidepressant medication to adolescents for minimal or mild depression is much less common than previous reported.

  • Space–Time Cluster Analysis to Detect Innovative Clinical Practices: A Case Study of Aripiprazole in the Department of Veterans Affairs

    by Robert B. Penfold, James F. Burgess, Austin F. Lee, Mingfei Li, Christopher J. Miller, Marjorie Nealon Seibert, Todd P. Semla, David C. Mohr, Lewis E. Kazis, Mark S. Bauer

    Objective: To identify space–time clusters of changes in prescribing aripiprazole for bipolar disorder among providers in the VA.Data Sources: VA administrative data from 2002 to 2010 were used to identify prescriptions of aripiprazole for bipolar disorder. Prescriber characteristics were obtained using the Personnel and Accounting Integrated Database.Study Design: We conducted a retrospective space–time cluster analysis using the space–time permutation statistic.Data Extraction Methods: All VA service users with a diagnosis of bipolar disorder were included in the patient population. Individuals with any schizophrenia spectrum diagnoses were excluded. We also identified all clinicians who wrote a prescription for any bipolar disorder medication.Principal Findings: The study population included 32,630 prescribers. Of these, 8,643 wrote qualifying prescriptions. We identified three clusters of aripiprazole prescribing centered in Massachusetts, Ohio, and the Pacific Northwest. Clusters were associated with prescribing by VA‐employed (vs. contracted) prescribers. Nurses with prescribing privileges were more likely to make a prescription for aripiprazole in cluster locations compared with psychiatrists. Primary care physicians were less likely.Conclusions: Early prescribing of aripiprazole for bipolar disorder clustered geographically and was associated with prescriber subgroups. These methods support prospective surveillance of practice changes and identification of associated health system characteristics.


  • Open Access

    Patterns of initiation of second generation antipsychotics for bipolar disorder: a month-by-month analysis of provider behavior

    by Christopher J Miller, Mingfei Li, Robert B Penfold, Austin F Lee, Eric G Smith, David N Osser, Laura Bajor, Mark S Bauer

    Several second generation antipsychotics (SGAs) received FDA approval for bipolar disorder in the 2000s. Although efficacious, they have been costly and may cause significant side effects. Little is known about the factors associated with prescribers’ decisions to initiate SGA prescriptions for this condition. We gathered administrative data from the Department of Veterans Affairs on 170,713 patients with bipolar disorder between fiscal years 2003–2010. Patients without a prior history of taking SGAs were considered eligible for SGA initiation during the study (n =126,556). Generalized estimating equations identified demographic, clinical, and comorbidity variables associated with initiation of an SGA prescription on a month-by-month basis. While the number of patients with bipolar disorder using SGAs nearly doubled between 2003 and 2010, analyses controlling for patient characteristics and the rise in the bipolar population revealed a 1.2% annual decline in SGA initiation during this period. Most medical comorbidities were only modestly associated with overall SGA initiation, although significant differences emerged among individual SGAs. Several markers of patient severity predicted SGA initiation, including previous hospitalizations, psychotic features, and a history of other antimanic prescriptions; these severity markers became less firmly linked to SGA initiation over time. Providers in the South were somewhat more likely to initiate SGA treatment. The number of veterans with bipolar disorder prescribed SGAs is rising steadily, but this increase appears primarily driven by a corresponding increase in the bipolar population. Month-by-month analyses revealed that higher illness severity predicted SGA initiation, but that this association may be weakening over time.


  • Erratum to: Use of Antipsychotic Medications in Pediatric Populations: What do the Data Say?

    by Robert B. Penfold, Christine Stewart, Enid M. Hunkeler, Jeanne M. Madden, Janet R. Cummings, Ashli A. Owen-Smith, Rebecca C. Rossom, Christine Y. Lu, Frances L. Lynch, Beth E. Waitzfelder, et al.

  • Use of Antipsychotic Medications in Pediatric Populations: What do the Data Say?

    by Robert B. Penfold, Christine Stewart, Enid M. Hunkeler, Jeanne M. Madden, Janet R. Cummings, Ashli A. Owen-Smith, Rebecca C. Rossom, Christine Y. Lu, Frances L. Lynch, Beth E. Waitzfelder, et al.

    Recent reports of antipsychotic medication use in pediatric populations describe large increases in rates of use. Much interest in the increasing use has focused on potentially inappropriate prescribing for non-Food and Drug Administration-approved uses and use amongst youth with no mental health diagnosis. Different studies of antipsychotic use have used different time periods, geographic and insurance populations of youth, and aggregations of diagnoses. We review recent estimates of use and comment on the similarities and dissimilarities in rates of use. We also report new data obtained on 11 health maintenance organizations that are members of the Mental Health Research Network in order to update and extend the knowledge base on use by diagnostic indication. Results indicate that most use in pediatric populations is for disruptive behaviors and not psychotic disorders. Differences in estimates are likely a function of differences in methodology; however, there is remarkable consistency in estimates of use by diagnosis.


  • Open Access

    Clinician identification of youth abusing over-the-counter products for weight control in a large U.S. integrated health system

    by S Bryn Austin, Robert B Penfold, Ron L Johnson, Jess Haines, Sara Forman

    Abuse of over-the-counter (OTC) products, such as diet pills and laxatives, for weight control by adolescents is well-documented and can precipitate serious medical conditions. Yet only a small percentage of youth with disordered weight control behaviors receive treatment. The objective of this study was to examine how often clinicians communicate with youth with symptoms consistent with abuse of OTC products for weight control about possible use of these products.


  • Heterogeneity in Aripiprazole Diffusion for Bipolar Disorder Treatment in the Veterans Health Administration

    by Robert B. Penfold, Amy M. Kilbourne, David C. Mohr, Zongshan Lai, Marjorie Nealon Seibert, Mark S. Bauer

    Objectives: The objectives of this study were to ascertain the relative importance of scientific "approval" versus U.S. Food and Drug Administration (FDA) regulatory approval regarding changes in aripiprazole prescribing rates for treating bipolar disorder and to identify system-level covariates associated with faster regional uptake of aripiprazole. Methods: Medication use data for 2002-2009 were obtained from the Veterans Health Administration (VITA) National Psychosis Registry for 106,547 patients with diagnoses of bipolar disorder, aggregated at the level of the Veterans Integrated Service Network (VISN). VISN-level independent variables were obtained from several VITA organizational databases. Interrupted time-series analysis was used to examine changes in rates of prescribing aripiprazole, and logistic regression was used to model above- versus below-median growth in aripiprazole prescribing across VISNs. Results: Three inflections were observed, corresponding to the publication of two positive studies and FDA approval of aripiprazole for the treatment of bipolar mania. No significant VISN-level policy, administrative, or staffing predictors of the growth rate in aripiprazole prescribing were identified. Exploratory analyses showed that access to care may play a role in uptake, whereas competing demands, such as substance abuse treatment needs, may retard adoption. Conclusions: Early published evidence may have a strong impact on practice for low-barrier innovations, such as newly marketed medications or changes in indication for approved medications. Regional targeting of prescriber behavior interventions may maximize efficiency in efforts to change prescribing; further delineation of factors associated with regional heterogeneity in prescribing would support such efforts. (Psychiatric Services 63:1178-1185, 2012; doi: 10.1176/appi.ps.201200061)


  • Open Access

    Reliability of a patient survey assessing cost-related changes in health care use among high deductible health plan enrollees

    by Robert B Penfold, Jeffrey T Kullgren, Irina Miroshnik, Alison A Galbraith, Virginia L Hinrichsen, Tracy A Lieu

    Recent increases in patient cost-sharing for health care have lent increasing importance to monitoring cost-related changes in health care use. Despite the widespread use of survey questions to measure changes in health care use and related behaviors, scant data exists on the reliability of such questions.